Literature DB >> 9488453

Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit.

J Yu1, Y Zhang, J McIlroy, T Rordorf-Nikolic, G A Orr, J M Backer.   

Abstract

We propose a novel model for the regulation of the p85/pl10alpha phosphatidylinositol 3'-kinase. In insect cells, the p110alpha catalytic subunit is active as a monomer but its activity is decreased by coexpression with the p85 regulatory subunit. Similarly, the lipid kinase activity of recombinant glutathione S-transferase (GST)-p110alpha is reduced by 65 to 85% upon in vitro reconstitution with p85. Incubation of p110alpha/p85 dimers with phosphotyrosyl peptides restored activity, but only to the level of monomeric p110alpha. These data show that the binding of phosphoproteins to the SH2 domains of p85 activates the p85/p110alpha dimers by inducing a transition from an inhibited to a disinhibited state. In contrast, monomeric p110 had little activity in HEK 293T cells, and its activity was increased 15- to 20-fold by coexpression with p85. However, this apparent requirement for p85 was eliminated by the addition of a bulky tag to the N terminus of p110alpha or by the growth of the HEK 293T cells at 30 degrees C. These nonspecific interventions mimicked the effects of p85 on p110alpha, suggesting that the regulatory subunit acts by stabilizing the overall conformation of the catalytic subunit rather than by inducing a specific activated conformation. This stabilization was directly demonstrated in metabolically labeled HEK 293T cells, in which p85 increased the half-life of p110. Furthermore, p85 protected p110 from thermal inactivation in vitro. Importantly, when we examined the effect of p85 on GST-p110alpha in mammalian cells at 30 degrees C, culture conditions that stabilize the catalytic subunit and that are similar to the conditions used for insect cells, we found that p85 inhibited p110alpha. Thus, we have experimentally distinguished two effects of p85 on p110alpha: conformational stabilization of the catalytic subunit and inhibition of its lipid kinase activity. Our data reconcile the apparent conflict between previous studies of insect versus mammalian cells and show that p110alpha is both stabilized and inhibited by dimerization with p85.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488453      PMCID: PMC108851          DOI: 10.1128/MCB.18.3.1379

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  48 in total

1.  Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits.

Authors:  K H Holt; L Olson; W S Moye-Rowley; J E Pessin
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

2.  Direct association of p110 beta phosphatidylinositol 3-kinase with p85 is mediated by an N-terminal fragment of p110 beta.

Authors:  P Hu; J Schlessinger
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

3.  The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity.

Authors:  A Klippel; J A Escobedo; M Hirano; L T Williams
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

4.  Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation.

Authors:  B Cheatham; C J Vlahos; L Cheatham; L Wang; J Blenis; C R Kahn
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

5.  Identification of two SH3-binding motifs in the regulatory subunit of phosphatidylinositol 3-kinase.

Authors:  R Kapeller; K V Prasad; O Janssen; W Hou; B S Schaffhausen; C E Rudd; L C Cantley
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

6.  Activation of phosphatidylinositol-3' kinase by Src-family kinase SH3 binding to the p85 subunit.

Authors:  C M Pleiman; W M Hertz; J C Cambier
Journal:  Science       Date:  1994-03-18       Impact factor: 47.728

7.  Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85.

Authors:  P Hu; A Mondino; E Y Skolnik; J Schlessinger
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

8.  PI 3-kinase: structural and functional analysis of intersubunit interactions.

Authors:  R Dhand; K Hara; I Hiles; B Bax; I Gout; G Panayotou; M J Fry; K Yonezawa; M Kasuga; M D Waterfield
Journal:  EMBO J       Date:  1994-02-01       Impact factor: 11.598

9.  Involvement of phosphoinositide 3-kinase in insulin- or IGF-1-induced membrane ruffling.

Authors:  K Kotani; K Yonezawa; K Hara; H Ueda; Y Kitamura; H Sakaue; A Ando; A Chavanieu; B Calas; F Grigorescu
Journal:  EMBO J       Date:  1994-05-15       Impact factor: 11.598

10.  PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity.

Authors:  R Dhand; I Hiles; G Panayotou; S Roche; M J Fry; I Gout; N F Totty; O Truong; P Vicendo; K Yonezawa
Journal:  EMBO J       Date:  1994-02-01       Impact factor: 11.598

View more
  208 in total

1.  Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo.

Authors:  B Vanhaesebroeck; K Higashi; C Raven; M Welham; S Anderson; P Brennan; S G Ward; M D Waterfield
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

2.  Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases.

Authors:  C A Beeton; E M Chance; L C Foukas; P R Shepherd
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

3.  The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling.

Authors:  Zheng Fu; Eliah Aronoff-Spencer; Jonathan M Backer; Gary J Gerfen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

4.  The conserved phosphoinositide 3-kinase pathway determines heart size in mice.

Authors:  T Shioi; P M Kang; P S Douglas; J Hampe; C M Yballe; J Lawitts; L C Cantley; S Izumo
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

5.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

6.  Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit.

Authors:  K Ueki; P Algenstaedt; F Mauvais-Jarvis; C R Kahn
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

7.  The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch.

Authors:  Zheng Fu; Eliah Aronoff-Spencer; Haiyan Wu; Gary J Gerfen; Jonathan M Backer
Journal:  Arch Biochem Biophys       Date:  2004-12-15       Impact factor: 4.013

8.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Authors:  Minghao Sun; Jonathan R Hart; Petra Hillmann; Marco Gymnopoulos; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

9.  miR-221 is required for endothelial tip cell behaviors during vascular development.

Authors:  Stefania Nicoli; Carl-Philipp Knyphausen; Lihua J Zhu; Abirami Lakshmanan; Nathan D Lawson
Journal:  Dev Cell       Date:  2012-02-14       Impact factor: 12.270

Review 10.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.